SCHEMBL5742589

SCHEMBL5742589

CC(=O)Nc1ccc(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]2C(=O)CO[C@@H]2C)cc1

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CTSK P43235 20/20 0.51
CTSL P07711 5/20 0.46
CTSS P25774 5/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5743408 0.90 CTSK (0.49) CTSKCTSLCTSS
SCHEMBL6476941 0.90 CTSK (0.52) CTSKCTSLCTSS
SCHEMBL5742914 0.89 CTSK (0.56) CTSKCTSLCTSS
SCHEMBL5742121 0.87 CTSK (0.56) CTSKCTSLCTSS
SCHEMBL6486332 0.87 CTSK (0.56) CTSKCTSLCTSS
SCHEMBL6486520 0.87 CTSK (0.49) CTSKCTSLCTSS
SCHEMBL5742033 0.86 CTSK (0.46) CTSKCTSLCTSS
SCHEMBL5744398 0.86 CTSK (0.67) CTSKCTSLCTSS
SCHEMBL5741753 0.86 CTSK (0.52) CTSKCTSLCTSS
SCHEMBL5741180 0.86 CTSK (0.67) CTSKCTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358183-B1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2006-04-12 EP disclosed
US-20050070598-A1 Cysteine protease inhibitors MEDIVIR AB (SE) 2005-03-31 US disclosed
US-20040229915-A1 Cysteine protease inhibitors MEDIVIR AB (SE) 2004-11-18 US disclosed
EP-1358183-A2 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2003-11-05 EP disclosed
US-20030186962-A1 Cysteine protease inhibitors MEDIVIR AB (SE) 2003-10-02 US disclosed
WO-2002088106-A2 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2002-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186962-A1 Cysteine protease inhibitors C1R, CTSS, CTSZ CTSK 4/4885CTSL 10/4885CTSS 2/4885
US-20050070598-A1 Cysteine protease inhibitors CTRL, CTSZ, CTSS CTSK 5/4885CTSL 13/4885CTSS 3/4885
US-20040229915-A1 Cysteine protease inhibitors C1R, CTRL, CTSK CTSK 3/4885CTSL 9/4885CTSS 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.